NEW YORK, May 27, 2015 /PRNewswire/ -- US-Australian
drug discovery and development company, Novogen Limited (ASX: NRT;
NASDAQ: NVGN), announced today that it will present at the Brain
Tumor Biotech Summit 2015, being held in New York on May 29,
2015. The venue is the Lennox Hill Hospital, East
76th St, Manhattan.
The Brain Tumor Biotech Summit brings together the nation's top
cancer specialists, biotechnology companies, the pharmaceutical
industry and the investment community to promote innovative new
therapies for brain tumors.
The Brain Tumor Biotech Summit is sponsored by The Brain Tumor
Biotech Center at The Feinstein Institute for Medical Research and
Voices Against Brain Cancer.
Novogen has been invited to present at this prestigious event
because of its recent collaboration with the Feinstein with the
objective of bringing the drug candidate, TRXE-009, into the clinic
as a treatment for both adult and pediatric brain cancers.
Novogen Group CEO, Graham Kelly PhD, will be reviewing the
status of the TRXE-009 program and the data in support of the
Company's belief that this molecule represents a major new
initiative in the search for an effective chemotherapy approach to
both primary and secondary brain cancers.
About TRXE-009
TRXE-009 is a small molecule cytotoxic. It belongs to the
super-benzopyran family of compounds that express pan anti-cancer
activity through disruption of the cancer cell's capacity to
maintain trans-membrane electron potential in vital structures such
as mitochondria. TRXE-009 shows strong anti-cancer activity in
animals against a variety of cancer phenotypes including melanoma
and prostate and on that basis is being brought into a first-in-man
study in 2016 for solid cancers. However, it also shows strong
cytotoxicity against cancer cells of neural origin including
glioblastoma, medulloblastoma and diffuse intrinsic pontine glioma,
leading to a parallel program designed to optimise the drug
formulation to ensure maximum access of the drug candidate to
tumors within the brain.
About Novogen
Novogen is a public, Australian-US drug development company
whose shares trade on both The Australian Securities Exchange (NRT)
and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc,
a joint venture company with Yale
University. Novogen has two drug technology platforms
yielding drug candidates that are first-in-class with potential
application across a broad range of degenerative diseases. In the
oncology field, the ultimate objective is to see both drug
technologies used in combination as first-line therapy across most
forms of cancer, with the objective of preventing tumor recurrence.
This objective is based on a strategy of achieving comprehensive
destruction of the full hierarchy of cells within a tumor with the
super-benzopyran technology platform killing the tumor-initiating
cells and the anti-tropomyosin technology, combined with vinca
alkaloids, to deliver a potent chemical debulking effect on their
daughter cells.
For more information, please visit www.novogen.com
About Voices Against Brain Cancer
Voices Against Brain Cancer's (VABC) mission is to find a cure
for brain cancer and brain tumors by advancing scientific research,
increasing awareness, creating a brain cancer and tumor community,
and supporting patients, their families and caregivers afflicted
with this devastating disease.
VABC has a wide variety of initiatives in motion for brain
cancer research, awareness and support. The organization's research
grants fund cutting-edge programs that will have a monumental
impact on the diagnosis and treatment of brain cancer and brain
tumors. Currently, these grants are being funded at numerous
esteemed institutions including: Baylor
University, Boston Children's Hospital / Harvard, Brain Tumor Biotech Center / Feinstein Institute / North Shore LIJ Health
System, Brookhaven National Laboratory, Central Brain Tumor
Registry Of The United States, Children's Hospital Of Philadelphia,
Cleveland Clinic, Columbia,
Cornell, Dana
Farber / Harvard, Duke, The Feinstein Institute / North Shore LIJ
Health System, Harvard, Hofstra / North Shore LIJ School Of Medicine,
Johns Hopkins, Lenox Hill Hospital /
North Shore LIJ Health System, Long Island Brain Tumor Center, NY,
Lurie Children's Hospital / Northwestern, Massachusetts General Hospital / Harvard, MD Anderson, Memorial Sloan Kettering,
New York University, Northwestern University, Ohio
State University, Rush
University, Stony Brook
University, University Of California
Davis, University Of California
Irvine, University Of California Los
Angeles, University Of California San
Diego, University Of California San
Francisco, University Of
Chicago, University Of Michigan,
University Of Pittsburgh, University Of
Texas San Antonio, University Of
Virginia, Vanderbilt University,
Wake Forest, Washington University, Yale and more.
For more information, visit
http://www.voicesagainstbraincancer.org/
About the Brain Tumor Biotech Center
The Brain Tumor Biotech Center is an interactive hub for
scientists, clinicians and biotech companies in the neuro-oncology
space to join forces and accelerate the delivery of novel drugs to
patients living with brain tumors.
John A. Boockvar, MD, and
Marc Symons, PhD, are both
Co-Directors of the Brain Tumor Biotech Center.
For more information visit
http://www.feinsteininstitute.org/brain-tumor-biotech-center
About Lenox Hill Hospital
Lenox Hill Hospital, a member of the North Shore-LIJ Health
System, is a 652-bed, fully accredited, acute care hospital located
on Manhattan's Upper East Side
with a national reputation for outstanding patient care and
innovative medical and surgical treatments. US News &
World Report has ranked the hospital among the nation's top 50
in Cardiology and Heart Surgery, and among the top 10 hospitals in
the state of New York with a total
of 10 "high performing" designations for its clinical performance
in Cancer, Diabetes & Endocrinology, Gastroenterology & GI
Surgery, Geriatrics, Gynecology, Nephrology, Neurology &
Neurosurgery, Orthopedics, Pulmonology and Urology. It is also
recognized nationally as a leader maternal/child health and offers
a wide range of services in radiology, and medical and surgical
specialties. For more information, go to
www.lenoxhillhospital.org
Corporate
Contact
Dr. Graham
Kelly
Executive Chairman
& CEO
Novogen
Group
Graham.Kelly@novogen.com
+61-0-2-9472-4101
|
Media
Enquiries
Prue Kelly
Media
Officer
Novogen
Group
Prue.Kelly@novogen.com
+61-0-2-9472-4100
|
Forward looking statement
All statements other than statements of historical fact
included in this announcement including, without limitation,
statements regarding future plans and objectives of Novogen Limited
("Novogen") are forward-looking statements. When used in this
announcement, forward-looking statements can be identified by words
such as 'may', 'could', 'should', 'would', 'believes', 'estimates',
'targets', 'expects' or 'intends' and other similar words that
involve risks and uncertainties.
Such statements relate to future events and expectations and
as such involve known and unknown risks and uncertainties. These
risks and uncertainties include, among other things, market
conditions, weather risks, economic and political risks.
These statements are based on an assessment of present
economic and operating conditions, and on a number of assumptions
regarding future events and actions that, as at the date of this
announcement, are expected to take place. Such forward-looking
statements are not guarantees of future performance and involve
known and unknown risks, uncertainties, assumptions and other
important factors, many of which are beyond the control of Novogen,
its directors and management, which could cause Novogen's actual
results to differ materially from the results expressed or
anticipated in these statements.
Novogen cannot and does not give any assurance that the
results, performance or achievements expressed or implied by the
forward-looking statements contained in this announcement will
actually occur and investors are cautioned not to place undue
reliance on these forward-looking statements. Actual results,
actions, and developments may differ materially from those
expressed or implied by those forward-looking statements depending
on a variety of factors.
Novogen does not undertake to update or revise forward-
looking statements, or to publish prospective financial information
in the future, regardless of whether new information, future events
or any other factors affect the information contained in this
announcement, except where required by applicable law and stock
exchange listing requirements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/novogen-to-present-at-brain-tumor-biotech-summit-2015-300088980.html
SOURCE Novogen Ltd